Forbes: What Beauty Ingredient Follows Peptides in 2026?

Forbes is asking which active ingredient could take peptides' place as skincare's headline claim, in an analysis published this month that surveys emerging compounds without settling on one name. The report treats peptides as the incumbent hero active and frames the search for a successor as an open question rather than a settled trend.

What is Forbes asking about beauty's next hero ingredient?

The outlet's premise, per its own headline, is that peptides have run their course as the industry's default marketing hook and that brands are now testing which compound earns the next round of product launches. Forbes' reporting surveys "industry signals and consumer trends" shaping that shift, according to the summary accompanying the piece, but does not crown a single replacement.

Why did peptides become the incumbent?

Peptides are short chains of amino acids that skincare formulators use to signal skin cells to produce more collagen; the ingredient class moved from prescription-adjacent serums into mass-market moisturizers over the past several product cycles. That trajectory — from dermatology offices to drugstore shelves — is the pattern Forbes' sourcing suggests any successor ingredient would need to repeat.

Which compounds are in contention?

Forbes' available reporting does not name a specific front-runner. The piece instead canvasses multiple emerging compounds and the industry and consumer signals around them, leaving the field open rather than declaring a winner. Readers looking for the outlet's full list of candidates should consult the original Forbes analysis directly.

Two dates worth tracking

• Sept. 16, 2026: HTT News published companion explainers on retinol versus retinal and on building a science-backed routine, both tracking how an established active gets reformulated for new claims.
• Sept. 21, 2026: Five days later, Forbes raises the peptides succession question — a reminder that ingredient cycles in beauty now turn over in a matter of days of press coverage, not years of R&D disclosure.

How does this compare with the retinol-to-retinal shift?

The retinol-to-retinal transition offers the closest recent parallel: a well-established active (retinol) got a reformulated, faster-converting cousin (retinal) marketed as an upgrade rather than a replacement, as detailed in HTT's retinol vs. retinal explainer. Forbes' peptide question follows the same logic — asking not whether the category disappears, but what sits next to it on ingredient labels.

What can shoppers do while the field is still open?

Until a successor ingredient consolidates around clinical data and retailer shelf space, dermatology-adjacent guidance still favors routine fundamentals over chasing a single new active. HTT's science-backed routine guide lays out the sequencing steps that apply regardless of which ingredient wins the next marketing cycle. Shoppers can watch peptide-labeled products for now and treat any newly hyped compound with the same scrutiny peptides eventually earned: ask for the concentration, the delivery vehicle, and the clinical study behind the claim before paying a premium.

Artiglio is A coming-soon iPhone chief of staff for briefings and drafts. Not on the App Store yet.